<DOC>
	<DOCNO>NCT00521339</DOCNO>
	<brief_summary>The study test safety tolerability Apremilast twice day participant recalcitrant plaque type psoriasis .</brief_summary>
	<brief_title>Apremilast Safety PK Study Recalcitrant Plaque Psoriasis</brief_title>
	<detailed_description>This phase 2 , multicenter , open-label , study evaluate safety , tolerability , pharmacodynamics , pharmacokinetics efficacy Apremilast participant recalcitrant plaque-type psoriasis . Approximately 31 participant enrol receive 20 mg apremilast orally BID , participants non-responders 84 day apremilast , 30 mg Apremilast course two study treatment phase . The study consist four phase : Screening Phase - 35 day , Treatment Phase 84 day , Extension Phase 84 day Observational Follow-up Phase 28 day . During Treatment Phase , participant receive two 20 mg Apremilast capsule day . Following Treatment Phase , participant option continue treatment Extension Phase . During Extension Phase , participant either continued take two 20 mg dose escalate two 30 mg Apremilast day . Participants consider responder ( achieve Psoriasis Area Severity Index ( PASI-75 ) begin Extension Phase continue 20 mg twice per day ( BID ) remain participant receive 30 mg capsule BID . The Extension Phase introduce participant already complete study ; therefore , several participant never opportunity continue Extension Phase . All participant ask participate 4-week post-treatment observational follow-up phase either upon completion study upon discontinuation study drug participant terminate study early .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form Must male female subject ethnic origin race &gt; 18 year time consent Must document history plaquetype psoriasis least 6 month prior screen visit Subjects must fulfill criterion outline least one follow clinical category : Unresponsive standard systemic therapy , define clinical history , investigator 's opinion , i.e . inadequate response one adequate treatment course ( ) standard systemic therapy Intolerant receive ( e.g. , contraindication prescribe ) standard systemic therapy biological intervention psoriasis Must Static Physician Global Assessment ( sPGA ) score least 3 Body surface area ( BSA ) â‰¥ 10 % screening Must meet specify laboratory criterion : Must able adhere study visit schedule study protocol requirement Females childbearing potential ( FCBP ) must negative urine pregnancy test screening ( Visit 1 ) . In addition , FCBP must agree use two follow adequate form contraception method oral , injectable , implantable hormonal contraception ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide vasectomize partner study . A FCBP must agree pregnancy test every 4 week study medication . Males ( include vasectomy ) must agree use barrier contraception ( latex condom ) engage sexual activity FCBP History clinically significant ( determined investigator ) cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic , major disease Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Pregnant lactating female History active tuberculosis ( TB ) infection within 3 year prior screen visit . Infections occur &gt; 3 year prior entry must effectively treated History incompletely treat latent ( indicated positive PPD [ purify protein derivative ] skin result ) TB infection Clinically significant abnormality chest xray ( CXR ) screen Psoriasis flare within 30 day screen , define protocol Use systemic therapy psoriasis within 28 day Visit 2 ( Baseline ) . Topical therapy define protocol Adalimumab , etanercept , efalizumab infliximab use within 56 day Visit 2 ( Baseline ) Alefacept use within 180 day Visit 2 ( Baseline ) Phototherapy Ultraviolet light A ( UVA ) , Ultraviolet light B ( UVB ) , Psoralens longwave ultraviolet radiation ( PUVA ) within 28 day Visit 2 ( Baseline ) Use investigational drug within 28 day Visit 2 ( Baseline ) , 5 half life know ( whichever longer ) Clinically significant abnormality 12lead Electrocardiogram ( ECG ) screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Apremilast ,</keyword>
	<keyword>Psoriasis ,</keyword>
	<keyword>PASI-75 ,</keyword>
	<keyword>sPGA</keyword>
</DOC>